2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Focusing on the Role of the Advanced Bladder Cancer Care Team: Case Studies on Managing irAEs
Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
IO Therapies in the Advanced Bladder Cancer Clinic: Aligning Your Team for Success
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Future Directions in Bladder Cancer Treatment: The Experts Weigh In
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation